4 completed, 4 recruiting, 3 unknown, 2 active not recruiting. 15 Phase 2, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Completed 4, Recruiting 4, Unknown 3, Active not recruiting 2, Terminated 2 |
| Phase 1 | 6 | Completed 3, Active not recruiting 1, Terminated 1, Unknown 1 |
Follow tepotinib: new trials by email Literature Review of tepotinib trials Research Report on tepotinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial) Biospecimen Collection, Computed Tomography, Lymphoscintigraphy - Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 2 | Recruiting | SWOG Cancer Research Network | 56 | 2024-08-08 | 2026-10-09 |
| PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer Amivantamab, Tepotinib - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 3 | 2024-06-18 | 2026-09-11 |
| Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment Lazertinib, Tepotinib - Non-Small Cell Lung Cancer Metastatic | Phase 2 | Recruiting | Sehhoon Park | 47 | 2024-06-11 | 2026-09-10 |
| CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC Tepotinib - Advanced Non-Small Cell Lung Cancer With MET Mutations | Phase 1 / Phase 2 | Terminated | Criterium, Inc. | 2 | 2022-05-25 | 2023-10-18 |
| Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ Carcinoma Tepotinib plus paclitaxel - Gastric Cancer, Gastroesophageal-junction Cancer | Phase 1 / Phase 2 | Unknown | Hallym University Medical Center | 42 | 2022-03-01 | 2022-07-05 |
| The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs Alectinib, Cobimetinib, Vismodegib - Advanced Cancer, Solid Tumor | Phase 2 | Recruiting | Helsinki University Central Hospital | 250 | 2021-12-10 | 2026-11-10 |
| Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE) Tepotinib, Cetuximab - Colorectal Neoplasms | Phase 2 | Terminated | EMD Serono Research & Development Institute, Inc. | 3 | 2021-01-28 | 2022-12-22 |
| The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy Erlotinib, Trastuzumab, Trastuzumab emtansine - Breast Cancer, Gastrointestinal Cancer | Phase 2 | Unknown | Fondazione per la Medicina Personalizzata | 400 | 2020-10-07 | 2023-10-03 |
| Tepotinib in Solid Tumors Harboring MET Alterations Tepotinib - Solid Tumor, MET Exon 14 Skipping Mutation | Phase 2 | Unknown | Chungbuk National University Hospital | 100 | 2020-01-16 | 2020-12-02 |
| A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) Tepotinib, Osimertinib - Non-small Cell Lung Cancer | Phase 2 | Completed | EMD Serono Research & Development Institute, Inc. | 140 | 2019-09-19 | 2026-08-21 |
| Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION) Tepotinib - Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV | Phase 2 | Active not recruiting | EMD Serono Research & Development Institute, Inc. | 337 | 2016-09-13 | 2026-07-14 |
| The Drug Rediscovery Protocol (DRUP Trial) Panitumumab, Olaparib, Dabrafenib - Cancer, Tumors | Phase 2 | Recruiting | The Netherlands Cancer Institute | 1550 | 2016-08-01 | 2024-01-24 |
| c-Met Second-Line Hepatocellular Carcinoma Tepotinib - Carcinoma, Hepatocellular | Phase 1 / Phase 2 | Completed | Merck KGaA, Darmstadt, Germany | 66 | 2014-05-18 | 2022-08-24 |
| Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma Tepotinib 300 mg, Tepotinib 500 mg, Tepotinib 1000 mg - Carcinoma, Hepatocellular | Phase 1 / Phase 2 | Completed | Merck KGaA, Darmstadt, Germany | 117 | 2014-01-06 | 2022-08-24 |
| Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT) Tepotinib, Gefitinib, Pemetrexed - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Merck KGaA, Darmstadt, Germany | 88 | 2013-12-23 | 2022-11-08 |
Carcinoma, Non-Small-Cell Lung (7) · Neoplasms (3) · Carcinoma, Hepatocellular (2) · Adenocarcinoma (1) · Breast Neoplasms (1) · Colorectal Neoplasms (1) · Deafness, Autosomal Recessive 39 (1) · Gastrointestinal Neoplasms (1) · Hematologic Neoplasms (1) · Lung Neoplasms (1) · Stomach Neoplasms (1)
EMD Serono Research & Development Institute, Inc. (3) · Merck KGaA, Darmstadt, Germany (3) · Chungbuk National University Hospital (1) · Criterium, Inc. (1) · Fondazione per la Medicina Personalizzata (1) · Hallym University Medical Center (1) · Helsinki University Central Hospital (1) · M.D. Anderson Cancer Center (1) · SWOG Cancer Research Network (1) · Sehhoon Park (1) · The Netherlands Cancer Institute (1)
South Korea (7) · United States (6) · Italy (5) · China (4) · Spain (4) · Taiwan (4) · Belgium (3) · France (3) · Germany (3) · Netherlands (3) · Japan (2) · Malaysia (2) · Russia (2) · Singapore (2) · Austria (1)
Andrea Botticelli (1) · Dae Young Zang, Dr (1) · David R Camidge, MD, PhD (1) · E.E. Voest, prof. (1) · Katriina Jalkanen, MD, PhD (1) · Ki Hyeong Lee, M.D. (1) · Paolo Marchetti (1) · Paul K Paik (1) · Sehhoon Park (1) · Tejas Patil, MD (1) · Xiuning Le, MD,PHD (1)
PMID 35771259, PMID 32469185, PMID 32479794, PMID 33824476, PMID 33972742, PMID 35086719, PMID 35385993, PMID 35598186, PMID 36101520, PMID 36870947, PMID 36999526, PMID 37270698, PMID 37424386, PMID 37944528, PMID 38575731, PMID 38630551, PMID 40880848, PMID 41023484, PMID 41963505, PMID 41986720
2015 (1), 2016 (1), 2018 (1), 2019 (1), U10CA180888 (1)